Company news

Ucb S.A. news in 2025

Ucb S.A.'s news releases, calls and decks from 2025, newest first.

View company

Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care

September 10, 2025

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

August 29, 2025

UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment

August 5, 2025

UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community

July 8, 2025

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

June 27, 2025

UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference

June 20, 2025

Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.

June 17, 2025

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

June 12, 2025

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

June 11, 2025

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

May 19, 2025

Decks in 2025